The invention generally relates to surgical methods for occlusion of hollow structures and tissue fixation, and more particularly to methods for occluding or resecting an atrial appendage.
Embolic stroke is the one of the nation's leading mortality factors for adults, and is a major cause of disability. A common cause of embolic stroke is the release of thrombus formed in the left atrial appendage (“LAA”) resulting from atrial fibrillation. The LAA is a small windsock-like cavity that extends from the lateral wall of the left atrium generally between the mitral valve and the root of the left pulmonary vein. The LAA normally contracts with the left atrium during systole, thus preventing blood within the LAA from becoming stagnant. During atrial fibrillation, however, the LAA fails to vigorously contract due to the lack of synchronicity of the electrical signals in the left atrium. As a result, thrombus may form in the stagnant blood that pools within the LAA, which may subsequently be ejected into systemic circulation after a normal sinus rhythm is reinstituted.
Challenges exist for excluding or removing the LAA. For example, the LAA is extremely thin and friable, meaning that traditional methods of suturing or stapling often can result in bleeding. LAA procedures are typically performed when the patient is on a heart-bypass machine, and bleeding associated with the typical open or thorascopic methods of occlusion of the LAA generally becomes apparent once the patient is taken off the machine and the heart begins pumping again. If bleeding does occur through the suture or staple tissue incision points, the patient may need to be put back on the bypass machine to stop the bleeding which exposes the patient to significant additional risk and morbidity.
Known methods for preventing such problems with the LAA have drawbacks. For example, most of the previously-known percutaneous devices are designed for an ideal LAA anatomical structure, including a well-defined, symmetric, and typically circular ostium and expected depth and orientation of the LAA cavity. Other devices that employ a loop applied to the base of the LAA on the pericardial surface may abrade the pericardial surface, thus leading to potentially fatal cardiac pericarditis or pericardial tamponade. Other devices involve using expandable disks to clamp and collapse the LAA tissue, but these too rely on the LAA having reasonably symmetric and well-defined depth and anatomy and have issues around sealing at tissue puncture points.
The present disclosure involves devices and methods for using occlusion devices to exclude an atrial appendage and other related cardiac and vascular procedures. The devices and methods can be employed during open surgery or thoracoscopy. Occlusion devices described herein can be placed in a row at the edge of the left atrial appendage (LAA), for example, to cut off flow from the rest of the heart. Unlike prior art clips, the occluders can be precisely deployed at the desired locations, including in a non-linear pattern that follows the contours of tissue desired to be occluded and on varying tissue thicknesses where each locking element can accommodate a different thickness of tissue. The LAA can be simply excluded with the occluders, or it can be subsequently resected. The occlusion devices can also be used to close surgical incisions in fragile tissue such as the atria, which commonly experience post-operative bleeding with the use of regular sutures.
The invention also provides methods and devices for elevating or isolating the LAA from the rest of the heart in order to apply the occluders. Elevation and isolation can be performed using a laparoscopic device as described herein. It can be aided by using a sling made from synthetic material or animal tissue. The sling can be a noose-like or lasso-like structure of adjustable width that wraps around the base of the LAA and can be tightened with an adjustable tightening member to snugly fit around the LAA.
While procedures involving the LAA are described extensively throughout the present disclosure, it is to be understood that the devices and methods are useful for similar procedures involving the right atrial appendage (RAA), as well as other cardiac and vascular procedures, including atrial incision, atrial volume reduction, ventricular aneurysms, arterial plication for the aortic ectasia or pulmonary artery, cholecystectomy, and numerous other laparoscopic or open procedures to close off vessels, clamp tissues, or any procedures that involve occluding, suturing, resecting, amputating, or stopping blood or fluid flow. Occlusion devices, delivery devices, uses, methods, and related procedures are described in US 2015/0173765, incorporated herein by reference. The present invention provides devices and methods for sealing the region surrounding the tissue puncture site or transfixion points.
In certain aspects, the invention provides a method for occluding an atrial appendage. The method includes deploying an occluder device transfixing a first wall and a second wall of an atrial appendage. In some embodiments, the method involves deploying a plurality of occluders. In some embodiment the method includes deploying at least one occluder element that transfixes a distal wall and at least one occluder element that transfixes a proximal wall, and the occluder elements are clamped together and locked together thereby occluding the hollow structure. In some embodiments, the method includes delivering the occluders via a delivery tube that is a needle or a laparoscopic device. The occluders may be two-part occluders including a distal implant and a proximal implant configured to lock together. The occluder device may be configured to assume a diametrically-reduced configuration for loading into a delivery tube and a diametrically-expanded configuration for deployment adjacent to the atrial appendage.
In embodiments, the method may include encircling the atrial appendage with a sling to lift the atrial appendage away from other heart tissue. In other embodiments the sling is used to support and reinforce to minimize tearing or breaking when the occluder element is deployed through it and the atrial appendage tissue, or project extended closure force on the atrial appendage tissue in the spaces between occluders. The sling can be made of a synthetic polymer or animal tissue and it can include a suture and an adjustment member in a noose configuration. The atrial appendage may be occluded with the sling before deploying the occluder. In some embodiments, the atrial appendage is lifted away from other heart tissue by the sling. A protective device can be placed between the atrial appendage and the other heart tissue or veins and arteries to protect them. In some embodiments, the occluders are placed through one part of the sling, through two walls of the atrial appendage, and through another part of the sling.
In some embodiments, the method also includes amputating the atrial appendage after deployment of the plurality of occluders.
The present invention provides devices and methods for using occlusion devices to exclude an atrial appendage. The invention can be employed during open surgery or thoracoscopy. The invention generally involves placing a row of occlusion clamps at the edge of the left atrial appendage (LAA) to cut off flow from the rest of the heart. The LAA can be simply excluded with the occluders, or it can be subsequently resected.
The invention also provides methods and devices for elevating or isolating the LAA from the rest of the heart before applying the occluders. Elevation can be performed using a laparoscopic device as described herein. It can be aided by using a sling made from a synthetic polymer such as polyethylene terephthalate or PTFE. Alternatively it can be made of animal tissue such as pig or human tissue. The sling can be a noose-like structure that wraps around the base of the LAA and can be tightened with an adjustable tightening member to snugly fit around the LAA. The sling can be various widths, from a narrow suture-like device, to a broad sheet up to several centimeters in width. In embodiments using broader slings, the occluder devices can be placed through a sling that has been wrapped around the LAA.
Occlusion devices for use with the present invention are described in U.S. patent application Ser. No. 13/348,416, filed Jan. 11, 2012; U.S. patent application Ser. No. 13/857,424, filed Apr. 5, 2013; and U.S. patent application Ser. No. 14/272,304, filed May 7, 2014, each of which is incorporated by reference herein in its entirety. The delivery device can be a hollow needle or a laparoscopic device. The delivery device can be configured to contain one or more occluders. Delivery devices for use with the present invention are described, for example, in U.S. patent application Ser. No. 14/639,814, filed Mar. 5, 2015 (published as US 2015/0173765) and U.S. patent application Ser. No. 15/226,577, filed Aug. 2, 2016, incorporated by reference herein in their entirety. Occluders may have a polymeric or organic coating to prevent rubbing against surrounding tissue and causing erosion or damage.
Throughout this disclosure, the terms “tubular structure” and “vessel” are used interchangeably to mean anatomical structures that can be occluded, including the LAA. It will be appreciated, however, that the methods of the present invention can be applied to occlusion of structures other than the LAA.
Atrial Appendage Procedures
Referring to
Occluding or resecting the LAA according to the present disclosure involves placing one or more occlusion clamps along the LAA to cut off flow from the rest of the heart. Various methods and devices for performing such a procedure are described herein.
Optionally a sling can be used in conjunction with the occluders. The sling may help to elevate the LAA away from the heart or it may combine with the occluders to provide additional pressure. The occluders, however, are configured to occlude the LAA with or without the sling.
The sling 400 allows the LAA 16 to be lifted up and manipulated. Upon tightening (
Once the sling 400 is tightened, occlusion clamps 455 can be inserted through the LAA to transfix opposing walls of the LAA, as shown in
Occlusion can be the final step of the procedure, or in some cases, the LAA 16 may be amputated. The LAA 16 can be amputated at or near the position of the occluders. Occlusion may be performed with or without the sling described above. The procedure can be performed on a beating or non-beating heart.
The invention contemplates other embodiments of the sling as well. As discussed above, the LAA is made of fragile tissue, which may be damaged by traditional methods of suturing or stapling, leading to excessive bleeding. The sling of the present invention can be a broader piece of material, which can compress a wider area of the LAA through which the occluders can be inserted. The compression supports the area around where the occluders penetrate the LAA tissue and prevents bleeding.
Accordingly,
The sling can be shaped (for example, at the time of surgery by the surgeon) to conform to the edge of the LAA. By doing so, the occlusion line can be accurately defined. That helps ensure that the entire LAA is removed, and prevents leaving part of the appendage, which may result in clot formation and distal emboli.
Various accessory instruments are contemplated for use with the present invention. For example, a retractor can be used in conjunction with a guard placed on the left ventricle under the LAA to prevent misplacement of the penetrating needle during delivery of occluding elements. Such protective devices and methods are described in more detail below. In certain embodiments, the retractor may be solid or may have an adjustable width. It may include a reflective surface (such as a mirror) so that needle penetration and distal occluder clip deployment can be observed.
Lifting the LAA 16 away from the heart allows a metal plate, or mirror or mirror like structure, or other protector to be placed between the area to be occluded and the rest of the heart. Various devices are disclosed that are useful for protecting surrounding tissue from that which is to be occluded.
Sling devices of the present invention can be used in conjunction with protector devices that shield non-target tissue from the occluders and occluder delivery devices. For example, a sling can be placed on the LAA and then used to pull the LAA away from the heart, so that a protective device can be placed underneath. Various devices for protecting surrounding tissue are disclosed below, and with reference to
In the embodiment shown in
By deploying occluders with the jaw-like devices of
Other devices and methods for protecting surrounding tissue are described in U.S. Patent Publication 2015/0173765, incorporated by reference.
The circular interdigitation of the occluder fingers securely brings the tissue together and provides a complete hemostatic area. The flexibility of the fingers allows the occluders to accommodate various tissue thicknesses. The occluders create an area of compression that extends beyond the perimeter created by the fingers, thus allowing them to be placed with a space between them, thus requiring fewer occluders to complete the suture line.
Importantly, because the occluders can each be placed at a location of the clinician's choosing, they do not have to conform to a linear path along the LAA or other structure to be closed off. The occluders can be used to create a non-linear line of occlusion. This is especially important for atrial appendage procedures because the orifice of the atrial appendage is non-linear. The occluders are thus more effective than linear clamps known in the prior art. Allowing the occluders to be placed non-linearly along the orifice of the LAA prevents the creation of residual recesses where a clot can form. Most current devices for LAA failed because they are clamp-like structures that cannot follow the shape of the orifice and thus leave recesses of the LAA and do not prevent later embolization.
The occluders alone are capable of closing off the LAA without the use the sling described above. In some embodiments, it may be desirable to eliminate the sling, which reduces the thickness of the area of occlusion and allows the occluders to interdigitate better. In other embodiments, the sling may be desirable.
In an embodiment, devices and methods of the invention are useful for occlusion of tubular structures with polymeric occlusion elements that are resorbable. The occlusion elements can resorb over time, leaving the downstream tissue fused, but no residual occluder element.
In other embodiments, the occluder can be used in conjunction with laser or RF ablation for treatment of various conditions including venous reflux. By occluding the vessel with our occluder upstream, e.g., at the Sapheno-femoral junction, the occluder acts to deflate the vessel, as it stops blood flow into the vessel, collapsing the vessel, and as a result reduces the separation between the walls of the vessel and the laser or RF probes which in turn, reduces the amount of energy needed to be deployed by laser or RF ablation, and as a consequence can reduce or eliminate the need for tumescent anesthetic deployment surrounding the vessel. The tumescent step is a time consuming, uncomfortable step for the doctor and patient. Also, reducing the amount of energy imparted by the laser or RF probe can reduce the side effects to the patient and avoid the risk of burning the vessel tissue.
Another delivery device for delivering the disclosed occluders for any laparoscopic or open procedure is shown in
The delivery device 2620 can be configured to deliver any of the two-piece occluders disclosed herein to transfix opposing walls of heart chambers or vessels. As shown in
The delivery system is shown in
The occluder elements can be any that have been described herein or in related publication US 2015/0173765. The occluder elements can be loaded into the two jaws 2621 and 2622 of the device in their preformed shapes, as shown in
The occluder element cartridge 2630, as seen in
The delivery device 2620, also referred to as the occluder applier, is a clamp-like device (see
In embodiments, the clip applier 2620 may apply a different delivery or clamping force on each occluder device (i.e., two locking clips with built in rod) or two locking clips and pin, such that one occluder may be locked with very little separation between the proximal and distal occlusion elements, and a second occluder device will be deployed across thicker tissue at the same time with a larger separation between the proximal and distal elements. Sequential deployment of each of the clips occluding different tissue thicknesses is also possible.
The applier 2620 may be spring loaded, to accommodate the different thickness of tissue, or to apply different forces to lock the thicker and thinner tissues together. In another embodiment, the delivery jaws loaded with the occluding devices 2610 can be rotated (swiveled) so that occluders can be placed at any chosen point of the area where the edges of the heart (ventricle or atrium) need to be sealed together.
Delivery of the elements occurs when the jaws of the occluding element are placed at the chosen point, and the two edges to be sealed are compressed with delivery of the two occluding elements. The occlusion elements lock together transfixing the tissue.
Additional Embodiments of Occluder Devices
Occluder devices can take on various embodiments, as has been described. Additional embodiments of occlusion devices are shown in
In the embodiment shown in
In another embodiment, an occluder can be a single-piece device with a hollow center. It can be constructed, for example, out of a hollow tube with slits cut into each end of the tube to form a plurality of legs. The occluder can be made of nitinol or another superelastic material and can be fixed in its open state (shown in
As shown in
The occluder may be delivered with a rod having an operator-controllable expanding or reversible locking region at the end of the rod, as shown in
Several hollow occluders can be disposed within a delivery tube, as shown in
Another embodiment of an occluder is shown in
In other embodiments envisioned, the occluder fingers may be magnetic and deployed on either side of tubular structure or tissue to be occluded, without the need for a central, transfixing rod. In other embodiments, the magnetic fingers, which will attract each other across the tubular structure or tissue, may include a transfixing rod. In other embodiments the occluder may be composed of at least one circular magnetic disk.
In other embodiments the occluder element has a protective sheath, as shown in
The embodiment of
In some embodiments, both the proximal occlusion element and the distal occlusion element are hollow. When the device is in place, it thereby creates a sealed opening from the outside of a structure to the inside. The device can be used to create an access port or a similar type of opening to allow the entry or exit of a fluid or pressure. The port can also be for facilitating a surgical procedure. The device can therefore be used for a variety of procedures, including rapid ileostomy, loading a feeding tube, a hydrocephaly shunt to drain fluid, tracheostomy, chest wall drainage, arteriovenous fistula shunt, or creating a dialysis port. The device can be used to create an airway access or a venous access.
As seen in
Pullback Method of Occluder Delivery
A preferred method for delivering occluders to a tubular structure involves compressing or flattening the tubular structure, such as by pulling back on the distal implant, before fully deploying the occluder device. The methods described herein can be employed laparoscopically, percutaneously, and in open surgical procedures. The method involves penetrating the tubular structure with a delivery device such as a needle and releasing a distal occlusion member on the far side of the tubular structure. When it is released from the delivery device, it assumes an expanded shape that is ideal for applying a force against the far side of the tubular structure.
Once the distal member is deployed in its expanded shape, the delivery device (while still coupled to the distal member) is pulled proximally, causing the distal member to exert a force on the far side of the tubular structure to bring the far side of the tubular structure into contact with the near side of the tubular structure, thereby closing the lumen between the far side and the near side. The tubular structure is thus caused to assume a compressed or flattened shape. The pulling of the far side of the tubular structure therefore occludes the lumen.
A proximal member is delivered to the near side of the collapsed tubular structure. The proximal member is locked together with the distal member, and together they apply a force directed at opposing walls of the tubular structure, thereby holding the tubular structure in the compressed state. The proximal member can thus be delivered in a controlled manner to the tubular structure that is already compressed. The occlusion that results from the pulling of the distal implant allows the two implants to come together more easily.
In other embodiments, the flattening of the tubular structure is achieved through the use of a separate instrument to compress the tubular structure before connecting the distal and proximal implants. The instrument can be some type of engaging member, such as a clamp that compresses the tubular structure, thereby occluding the lumen. The engaging member can be a laparoscopic device. It can be connected to the delivery device or it can be separate.
In certain aspects, the invention provides a method for occluding a tubular structure such as a blood vessel. The method includes penetrating a tubular structure with a hollow delivery device and deploying a distal implant on a far side of the tubular structure. The method further involves pulling back with the hollow delivery device to cause the distal implant to compress the tubular structure, thereby occluding the tubular structure. The method also involves deploying a proximal implant on the near side of the tubular structure to secure the tubular structure in its compressed state.
In certain embodiments, the the hollow delivery device is a needle. In other embodiments, the distal implant is made of a super elastic material that is configured to assume a compressed state for loading into the delivery device and an expanded state when released from the delivery device, and the proximal implant is made of a super elastic material that is configured to assume a compressed state for loading into the delivery device and an expanded state when released from the delivery device.
In embodiments, deploying the distal implant is done by pushing the distal implant out of the delivery device to cause it to assume its expanded state. In certain embodiments, the proximal implant is pushed out of the delivery device by a proximal implant delivery tube, and the distal implant is pushed out of the delivery device by a distal implant delivery tube disposed concentrically within the proximal implant delivery tube.
In other aspects, the invention provides a method for occluding a tubular structure such as a blood vessel. The method includes providing a hollow needle containing an occluder and providing an engaging member. The method further includes manipulating the engaging member against a tubular structure to compress a region of the tubular structure. The method also includes penetrating the compressed region of the tubular structure with the hollow needle. The method also includes deploying the occluder to occlude the tubular structure at the compressed region.
In some embodiments, the occluder includes a distal implant and a proximal implant. The distal implant can be made of a super elastic material that is configured to assume a compressed state for loading into the delivery device and an expanded state when released from the delivery device, and the proximal implant can be made of a super elastic material that is configured to assume a compressed state for loading into the delivery device and an expanded state when released from the delivery device.
In embodiments, deploying the distal implant is done by pushing the distal implant out of the delivery device to cause it to assume its expanded state. The needle may further include a proximal implant delivery tube and a distal implant delivery tube disposed concentrically within the proximal implant delivery tube.
In some embodiments, a vessel is pushed closed by the needle delivery device itself, prior to deployment of the occluder. Depending on the thickness of the needle wall, the outside diameter (OD) of the needle, and the sharpness of the needle, different delivery devices can be designed to cleanly pierce a vessel or to compress the vessel prior to puncturing it. Experiments with needles of various parameters have shown that, thin needle walls (for example, less than 0.15 mm) cause the needle to be more “bouncy” and push the tissue closed before puncturing it. Needles with thickness of around 0.2 mm or greater tend to directly puncture the vessel. Relative ratios of OD to wall thickness can impart different qualities on the delivery needle.
Although the method is described with respect to a tubular structure, such as a vein or a vessel, the method can be applied to other similar uses as well, including closing a hole in an anatomical structure or connecting two structures together.
In
In a demonstration of certain methods of the present invention, occlusion of an LAA was achieved by the following steps:
The results of the demonstration of the method were positive. The design of the occlusion elements and the flexibility properties of the nitinol were well demonstrated. No tearing of the LAA walls was noted. The interdigitation of the elements were again noted to be a critical and significant element of the occlusion efficiency of the occluder as well as reducing the occlusion line length and thus reducing the number of occluders required. Clearly enlarging the size of the occluder (enlarging the size of the “fingers” of the occluding elements) would minimize the number of occluders required.
The animal study, as shown in
Another use for the disclosed devices is to treat mitral insufficiency (or mitral regurgitation or mitral incompetence), which is a disorder of the heart in which the mitral valve does not close properly when the heart pumps out blood. Occluders of the present disclosure can be delivered to clamp together the leaflets of the mitral valve, thereby stabilizing the mitral valve and preventing the abnormal leaking of blood backwards from the left ventricle, through the mitral valve, into the left atrium, when the left ventricle contracts.
Varicose veins, estimated to effect approximately 23% of US adults, are part of a spectrum of chronic venous disease and is generally more common in women than men between the ages of 40-80 years. Untreated, varicose veins may eventually progress to severe chronic venous insufficiency with symptoms and other manifestations including lower extremity venous ulceration. The standard of care in the US for the treatment of varicose veins until the turn of the century was surgery with high ligation, stripping of the saphenous vein and phlebectomy of the presenting varicosities. More recently, alternative treatments for varicose veins including endothermal ablation with laser or radiofrequency have replaced surgery as the standard of care together with chemical treatments, sclerosants and chemical adhesives. These procedures have brought the treatment of varicose veins out of the hospital surgical operating rooms and into the outpatient surgical clinics, reducing hospital costs for patient management and minimizing patient morbidity; however, the underlying pathophysiological approach to the treatment of these patients has not changed. It remains aimed at preventing all reflux in the lower extremity veins with occlusion of a long segment of the saphenous vein from the sapheno-femoral junction, occlusion of large tributaries, and removal or hook-phlebectomy of the superficial varicosities.
In the early 1990's Claude Franceschi, described an alternative approach, saphenous sparing, to treat the venous insufficiency associated with varicose veins. This approach, known as “CHIVA” (Cure conservatrice et Hemodynamique de L'Issufsance veineuse en Ambulatoire or conservative hemodynamic cure for varicose veins), unlike the surgical and endovascular approaches, does not aim at elimination of all reflux in the lower extremity veins, but directs the flow of the “refluxing” blood into the deep veins of the lower extremity. CHIVA concept ultimately attempts to relieve the pressure in the superficial veins, eliminates the problem of superficial venous hypertension, and the clinical consequences of varicose veins.
This method of treatment has two main requirements, an accurate ultrasonic assessment of the flow patterns in the extremity veins to choose the optimal flow diversions that need to be performed, and accurate open surgical ligation. These minimally invasive surgical procedures require some surgical expertise. In addition, because multiple occlusions are required, they are also time consuming and can be disfiguring. Because of the combination of demanding ultrasonic expertise, and the associated surgical skills required to execute the plan, CHIVA has not been adopted by the majority of venous interventionalists. However, as a result of the expense of the endothermal or chemical ablation devices, there may be a developing interest in the CHIVA technique if simplified.
The occluders and methods described in the present disclosure provide an alternative simple, percutaneous, mechanical method of vessel occlusion with a device that eliminates the need for these time consuming and skilled surgical procedures. This technique will simplify and expedite the CHIVA procedure for the doctor and minimize patient's discomfort and recovery. The occluders can be delivered percutaneously or during open surgical procedures, in vessels up to 12 mm in diameter.
As described herein, occluders of the present invention can be preloaded into an 18G needle of a delivery device, such as the delivery devices described throughout the present disclosure. When deployed, the occluders transfix and occlude the target vessel. The occluder may include two stellate compression elements and a titanium fine strut which connects and locks the compression elements together. The proximal element, which compresses the near wall of the vessel, and distal element, which compresses the far wall of the vessel are made of nitinol, which once deployed, assumes its designated configuration closing off the vessel. The individual legs of the proximal occlusion component may be configured to alternate with and interdigitate with the individual legs of the distal occlusion component. This interdigitation is important as it obviates the problem with different vessel wall thicknesses and creates a zone of occlusion that surrounds the site of penetration, preventing leaks at the needle entry site.
In embodiments, the occluder deliver device delivers an occluder under ultrasound guidance. Clear identification of the vessel is essential in order to transfix the vessel by passing the needle through both walls of the vessel. A small opening in the transfixing needle allows the escape of blood as the needle enters into the lumen of the vessel to confirm accuracy of needle placement within the targeted vessel, as well as confirm the identity of the vessel, artery versus vein. Once the vessel is transfixed, further ultrasound guidance is not required. The two occluding elements are released, locked together and the vessel occluded. The delivery device is then detached and withdrawn.
In animal studies using a porcine model, 30 ultrasound guided percutaneous occlusions were successfully performed in vessels ranging from 2-12 mms. These vessels include the proximal femoral vessels, distal (superficial) femoral arteries and veins, carotid arteries and jugular veins. For the larger vessel size, >7 mm, a 2nd occluder clip was necessary to completely occlude the targeted vessel. In certain embodiments, the size of the clip can be determined by need; thus, for a larger vessel, a larger clip can be used.
All targeted vessels in this study were successfully occluded and occlusion confirmed by Duplex ultrasound as well as open surgical exposure. In addition, no injury to any of the adjacent structures was identified.
The occluder with its ability to accurately occlude vessels percutaneously under ultrasound guidance simplifies the technique of the CHIVA procedure. This novel occlusion device eliminates the need for “open” surgical procedures and thus minimizes the invasiveness of the CHIVA procedure. The simple, mechanical occlusion devices disclosed herein will allow a wider spectrum of caregivers to adopt the CHIVA approach, which is a more conservative approach with saphenous vein preservation for the treatment of symptomatic varicose veins and chronic venous insufficiency. It will also improve patient comfort and acceptance of the procedure, speed recovery and reduce procedural morbidity and the associated health care costs.
References and citations to other documents, such as patents, patent applications, patent publications, journals, books, papers, web contents, have been made throughout this disclosure. All such documents are hereby incorporated herein by reference in their entirety for all purposes.
Various modifications of the invention and many further embodiments thereof, in addition to those shown and described herein, will become apparent to those skilled in the art from the full contents of this document, including references to the scientific and patent literature cited herein. The subject matter herein contains important information, exemplification and guidance that can be adapted to the practice of this invention in its various embodiments and equivalents thereof.
This application claims the benefit of and priority to U.S. Provisional Application Ser. No. 62/267,825, filed Dec. 15, 2015; U.S. Provisional Application Ser. No. 62/267,883, filed Dec. 15, 2015; U.S. Provisional Application Ser. No. 62/276,042, filed Jan. 7, 2016; U.S. Provisional Application Ser. No. 62/299,444, filed Feb. 24, 2016; U.S. Provisional Application Ser. No. 62/299,662, filed Feb. 25, 2016; U.S. Provisional Application Ser. No. 62/303,071, filed Mar. 3, 2016; U.S. Provisional Application Ser. No. 62/306,932, filed Mar. 11, 2016; and U.S. Provisional Application Ser. No. 62/361,547, filed Jul. 13, 2016; and is a continuation-in-part of U.S. application Ser. No. 15/226,577, which claims the benefit of and priority to U.S. Provisional Application Ser. No. 62/203,655, filed Aug. 11, 2015, and U.S. Provisional Application Ser. No. 62/298,724, filed Feb. 23, 2016, and is a continuation-in-part of U.S. application Ser. No. 14/639,814, filed Mar. 5, 2015 (which claims the benefit of and priority to U.S. Provisional Application Ser. No. 62/084,989, filed Nov. 26, 2014), which is a continuation-in-part of U.S. application Ser. No. 14/272,304, filed May 7, 2014 (which claims the benefit of and priority to U.S. Provisional Application Ser. No. 61/948,241, filed Mar. 5, 2014, and U.S. Provisional Application Ser. No. 61/820,589, filed May 7, 2013), which is a continuation-in-part of U.S. application Ser. No. 13/857,424, filed Apr. 5, 2013 (which claims the benefit of and priority to U.S. Provisional Application Ser. No. 61/620,787, filed Apr. 5, 2012), which is a continuation-in-part of U.S. application Ser. No. 13/348,416, filed Jan. 11, 2012 (which claims the benefit of and priority to U.S. Provisional Application Ser. No. 61/431,609, filed Jan. 11, 2011); the entire contents of each of which are incorporated by reference herein in their entirety.
Number | Date | Country | |
---|---|---|---|
62203655 | Aug 2015 | US | |
62298724 | Feb 2016 | US | |
62361547 | Jul 2016 | US | |
62306932 | Mar 2016 | US | |
62303071 | Mar 2016 | US | |
62299662 | Feb 2016 | US | |
62299444 | Feb 2016 | US | |
62276042 | Jan 2016 | US | |
62267883 | Dec 2015 | US | |
62267883 | Dec 2015 | US | |
62084989 | Nov 2014 | US | |
61948241 | Mar 2014 | US | |
61820589 | May 2013 | US | |
61620787 | Apr 2012 | US | |
61431609 | Jan 2011 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 15226577 | Aug 2016 | US |
Child | 15380245 | US | |
Parent | 14639814 | Mar 2015 | US |
Child | 15226577 | US | |
Parent | 14272304 | May 2014 | US |
Child | 14639814 | US | |
Parent | 13857424 | Apr 2013 | US |
Child | 14272304 | US | |
Parent | 13348416 | Jan 2012 | US |
Child | 13857424 | US |